These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28317063)

  • 1. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis.
    Tam HH; Collins DJ; Brown G; Chau I; Cunningham D; Leach MO; Koh DM
    Br J Radiol; 2013 Oct; 86(1030):20130281. PubMed ID: 23995873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a Simplified Intravoxel Incoherent Motion (IVIM) Analysis of Diffusion-Weighted Imaging for Prediction of Tumor Size Changes and Imaging Response in Breast Cancer Liver Metastases Undergoing Radioembolization: A Retrospective Single Center Analysis.
    Pieper CC; Sprinkart AM; Meyer C; König R; Schild HH; Kukuk GM; Mürtz P
    Medicine (Baltimore); 2016 Apr; 95(14):e3275. PubMed ID: 27057887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
    Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
    J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
    Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
    J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.
    Saxena A; Chua TC; Bester L; Kokandi A; Morris DL
    Ann Surg; 2010 May; 251(5):910-6. PubMed ID: 20395859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.
    Kamel IR; Reyes DK; Liapi E; Bluemke DA; Geschwind JF
    J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):49-56. PubMed ID: 17296704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
    Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
    Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization in patients with hepatic metastases from breast cancer.
    Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK
    J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
    Dunfee BL; Riaz A; Lewandowski RJ; Ibrahim S; Mulcahy MF; Ryu RK; Atassi B; Sato KT; Newman S; Omary RA; Benson A; Salem R
    J Vasc Interv Radiol; 2010 Jan; 21(1):90-5. PubMed ID: 19939705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.
    Mulcahy MF; Lewandowski RJ; Ibrahim SM; Sato KT; Ryu RK; Atassi B; Newman S; Talamonti M; Omary RA; Benson A; Salem R
    Cancer; 2009 May; 115(9):1849-58. PubMed ID: 19267416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
    Tochetto SM; Töre HG; Chalian H; Yaghmai V
    AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.